

Lars Norgren, MD, PhD, FRCS

Dr. Norgren discusses the PAD 2009 meeting, his hopes for the field, and what's next for TASC II.

This year, you will lead the PAD 2009 meeting in Örebro, Sweden, May 12 and 13. What inspired you to establish this meeting, and what are its objectives this year?

As early as 1994, we started a cooperation between the UK and Sweden, soon also including the US, to discuss certain issues in vascular medicine, vascular surgery, and vascular biology. My colleagues and I organized this first meeting, Eurochap-94, in Sweden. Now, 15 years later, and after several meetings in this trans-Atlantic vascular medicine setting, and in an era of enormous technical developments, we think that—unlike many meetings—we should focus on expectations and requirements for the next 10 years. What research is needed, how could costs be met, who will pay? The implications for patients with peripheral artery disease are obvious because cardiovascular prevention is of the utmost importance, but also important is the management of symptoms, to what extent the walking restriction can and shall be treated by intervention, how the prognosis for critical limb ischemia should be improved, etc.

On this basis, we have invited keynote speakers from research organizations, regulators, and drug and device companies besides the vascular community to discuss such topics with the audience in plenary sessions. Speakers, and hopefully the audience, will come from the US, Europe, and other parts of the world.

What would you like to see happen in the field in the next decade?

I hope we could do more for patients with critical limb ischemia. Whether angiogenic therapy will become an alternative remains to be shown. The results of ongoing trials are eagerly awaited. More realistic is to say that I hope and even think that the awareness of peripheral artery disease will increase, in order to recognize its severity as a predictor for serious cardio- and cerebrovascular events, requiring prevention.

Do you anticipate there will be significant changes to the options available, or will the progress be limited to incremental advancements of current technologies?

If we look back, there has been a tremendous development in this area since the 1960s to 1970s, but still the steps have been rather small, except for the very specific Dotter breakthrough, the start of catheter technology. I do not believe the next 10 years will see any dramatic technical change but most likely better prevention and even more sophisticated catheter techniques. Should any real breakthrough be seen, it may be in the field of prevention of the development of atherosclerosis.

What makes me slightly worried is the fact that if open vascular surgery will be restricted to the very complicated cases, centralization of such cases is required, and in many countries, this will become problematic.

The TASC (Transatlantic Inter-Society Consensus) guidelines were revised to TASC II in 2007. What benefit have you seen as a result of these changes?

We have seen the “original” TASC being cited in more than 900 publications and realized that it has had some “harmonizing” effects on the management of our patients. The problem was that it was not recognized to any great extent by our referring colleagues in primary healthcare. That was the main reason to update and abbreviate into TASC II. This publication should create a basis for dissemination of the message in various countries to primary healthcare providers, general practitioners, etc. This is a process that goes on. Just 1 year has passed since the publication of TASC II, so let's wait a while to see what benefit will come out.

Can we expect the guidelines to change again within the next 10 years? Are there any changes that you believe are necessary?

As mentioned, the development is rapid. Small steps forward may mean that evidence increases, provided
(Continued on page 89)



(Continued from page 90)

Already at this stage, we have started one modification to be published separately. My colleagues have rightly commented that the TASC II chapter on interventions is not detailed enough to be useful for specialists because many lesions, classified C or even D, can be treated by catheter techniques—at least by centers of excellence.

What would you like to see happen to the relationship among the public, physicians, industry, and the government to improve the treatment of peripheral artery disease (PAD)?

As mentioned, for the patients, the awareness of the severity of PAD is a most important issue to be confirmed in everyday practice and not least in governmental advice. ■

Would you like to comment on an author's article? Do you have an article topic to suggest? We are interested in your feedback. Please email us at evteditorial@bmctoday.com with any thoughts or questions you have regarding this publication.

SERIAL WARNING: Refer to the Directions for Use supplied with any interventional device to be used in conjunction with the Cordis WALLSTENT Endoprostheses for their intended uses, contraindications and potential complications. The safety and efficacy of the Cordis WALLSTENT Endoprostheses have not been demonstrated with embolic protection devices other than the FilterWire EZ[®] System. Risk of distal embolization may be higher if the Cordis WALLSTENT Endoprostheses cannot be used in conjunction with the FilterWire EZ[®] System to protect the distal during stent placement procedures. The long-term performance of the Cordis WALLSTENT Endoprostheses has not been established. Stenting across a major bifurcation may hinder or prevent future diagnostic or therapeutic procedures. In patients requiring the use of antithrombotic or antiplatelet agents such as aspirin may be adversely affected. The implantation of the Cordis WALLSTENT Endoprostheses should be performed only under fluoroscopic observation with radiographic equipment providing high-resolution images. • Never advance the Cordis WALLSTENT Endoprostheses without the guide wire extending from the tip. • Do not advance the Cordis WALLSTENT Endoprostheses against any significant resistance. • The Cordis WALLSTENT Endoprostheses should be deployed in relation to the artery dilated by 1mm to 2mm to prevent migration. • Do not release the Cordis WALLSTENT Endoprostheses if unusual forces are required; in such a situation use another device. • Never advance partially deployed Cordis WALLSTENT Endoprostheses distally. • Recross the mark and repositioning of the Cordis WALLSTENT Endoprostheses should be strictly avoided when the partially deployed Cordis WALLSTENT Endoprostheses is already in contact with the plaque of the stenosis. • Use of this device in patients with hypersensitivity to cobalt, chromium, iron, nickel or molybdenum may provoke an allergic reaction. • Avoid using power injection in the central circulation. • Implanting a stent may lead to dissection of the vessel distal and/or proximal to the stent and may lead to thrombotic occlusion of the vessel. • The use of this device in a cordis endarterectomy, further dilation, or placement of additional stents. The stent may cause a thrombotic, distal embolization or may migrate from the site of implant down the arterial lumen. Appropriate stenting of the stent to the vessel is required to reduce the possibility of stent migration. In the event of thrombotic or expanded stent, thrombolysis and PTA should be attempted. • In the event of complications such as infection, pseudoaneurysm or fistulization, surgical removal of the stent may be required. • Overstretching of the artery may result in rupture and life threatening bleeding. • Gallium angioplasty of the cordis bifurcation may induce transient hemodynamic instability consisting of hypotension or hypotension. Appropriate pharmacologic therapy should be initiated.

Non-clinical testing for non-clinical testing, the Carotid WALLSTENT (Monorail Endoprostheses) (Carotid WALLSTENT Endoprostheses) has been shown to be safe at field strengths of 3.0 Tesla or less, and a maximum whole body averaged specific absorption rate (SAR) of 2.0 W/kg for 10 minutes of MRI exposure. The Carotid WALLSTENT Endoprostheses should not migrate in this MRI environment. Non-clinical testing has not been performed to rule out the possibility of stent migration at field strengths higher than 3.0 Tesla. MRI at 3.0 Tesla or less may be performed immediately following the implantation of the Carotid WALLSTENT Endoprostheses. MR image quality may be compromised if the stent is located in the exact same area or relatively close to the position of interest.

ADVERSE EVENTS: Events due to any cause. Life-threatening condition (e.g., stroke). Persistent or significant disability/incapacity. Any event resulting in an unscheduled inpatient hospitalization or prolongation of existing hospitalization >72 hours post index procedure. Any event requiring intervention, except for controlled administration of antiemetic, analgesic, or antipyretic, during the follow-up period. Congenital abnormality or birth defect. Serious adverse events have been coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 5.0 and are presented by System Organ Class and Preferred Term as follows: GLOID AND LYMPHATIC SYSTEM DISORDERS include events such as anemias, leukemias, lymphomas, myelodysplastic syndromes, and myelofibrosis. CARDIAC DISORDERS include events such as angina, arrhythmias, cardiac failure congestive and myocardial infarction. EYE DISORDERS include events such as conjunctivitis/infection.

POTENTIAL ADVERSE EVENTS: Abrupt vessel closure; Additional interventional or surgical treatment (e.g., stenting or carotid endarterectomy); Allergic reactions (including to antiseptic agents, contrast media, or x-ray materials); Anemia; Arteriovenous fistula; Atherosclerosis; Arrhythmias; Aortic aneurysm; Aortic dissection; Aortic regurgitation; Aortic stenosis; Basal ganglia hemorrhage; Bleeding; Bradycardia; Cerebral vascular event such as stroke; Cerebral ischemia/transient ischemic attack; Compensatory heart failure (CHF); Death; Detachment and/or implantation of a component; Emboli (air, tissue, plaque, thrombus, device or other); Fever; Filter thromboembolism; Hematoma; Hemorrhage; Hypertension; Infection; Hypotension/hypotensive reaction; Hypoxia; Infarction; Ischemia/infarction of tissue or organ; Myocardial infarction (MI); Pain; Pseudoaneurysm; Renal failure/nephrotoxicity; Reactions of stained pigment; Suture; Systemic embolization; Thrombotic events; Vessel occlusion or thrombosis.

CAUTION: Federal law (USAI) restricts this device to sale by or on the order of a physician.

FILTERWAVE® E2™ EMBOLIC PROTECTION SYSTEM
 Prior to use, please see the complete "Directions for Use" for more information on indications, Contraindications, Warnings, Precautions, Adverse Events and Operator's Instructions.
 The **FILTERWAVE® E2™ Embolic Protection System** is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary infarcted vessels. The device is designed to be used in coronary arteries with a diameter of 2.5mm to 3.5mm. The diameter of the filter at the site of filter loop placement should be between 2.5mm and 3.5mm. The safety and effectiveness of this device as an embolic protection system has not been established in the coronary vasculature, peripheral vessels other than carotid arteries, or in treating native coronaries, including acute myocardial infarction.

CONTRAINDICATIONS: Patients with severe allergy to heparin.
 • Patients with bleeding diathesis or other disorders which limit the use of anticoagulant therapy.

WARNING: Only physicians thoroughly trained in percutaneous, minimally-invasive techniques and procedures should use the FilterWire EZ System. The safety and effectiveness of coronary device deployment (CDD) when used with embolic protection devices has not been established. • The safety and effectiveness of the FilterWire EZ System has not been demonstrated with carotid stents other than the Carotid WALLSTENT® Monorail® Endoprotektalis System. • Avoid using power injection in the cerebral circulation. Filter safety and effectiveness has not been tested with power injection. • Failure to follow recommended device preparation and delivery instructions may result in air embolism. • Introduce and advance devices slowly to prevent air embolism or trauma to the vasculature. • Do not attempt to move the protection wire without observing the real-time response. • A distal wire tip has the potential to cause vessel injury. Confirm that the wire tip is in the vessel lumen. • Do not use the wire with any attempt to cross the lesion with the FilterWire EZ System. • Observe all protection wire movement in the vessel under fluoroscopic imaging. • Always keep the open filter loop distal to a deployed stent. Pulling the filter loop into the stent area may lead to entanglement with the stent and possible filter loop detachment. • Ensure that the protection wire is stabilized throughout the procedure. Failure to stabilize the protection wire could lead to redundant movement of the filter resulting in protection wire entanglement and/or delay in the procedure. • Do not pull excessively on the protection wire or the EZ Retrieval Sheath to avoid filter membrane tears, filter loop detachment or other damage to the device.

ADVERSE EVENTS: Possible adverse effects include, but are not limited to, the following: • Angina • Bleeding complications • Bradycardia or arrhythmias, including ventricular fibrillation or tachycardia • Congestive heart failure • Damage to or dislocation of the implanted device(s) • Death • Detachment and/or implantation of a component of the system • Drug reaction, allergic reaction to contrast media, medications or device materials • Emergent surgery • Embolization of air, tissue, thrombus or other embolic debris • End organ ischemia, vessel thrombosis or spasm • Hypertension/hypotension or • Infection (local or systemic) • Myocardial infarction • No-flow resulting from reduced blood flow through the FilterWire[®] System filter • Puncture site complications (i.e., vessel occlusion, hematoma, herniation, pseudoaneurysm or retroperitoneal hematoma) • Pseudoaneurysm • Renal dysfunction • Systemic embolization • Systemic thromboembolic event (SVE), transient ischemic attack (TIA) or stroke • Vessel damage, dissection, occlusion, aneurysm, perforation, rupture or injury. **CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician.

**Boston
Scientific**

Delivering what's next.™

Boston Scientific Corporation
One Boston Scientific Place
Natick, MA 01760-1537
www.bostonscientific.com
www.carotid.com

To order product or for
more information, contact
customer service at
1.888.272.1001.

© 2008 Boston Scientific Corporation
or its affiliates. All rights reserved.
USPW035.166.0 OCT08